(Q34858025)

English

Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

atherosclerosis

1 reference

based on heuristic

inferred from title

Louis M Havekes

7

object named as

Louis M Havekes

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

8

object named as

Ulf Landmesser

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Thomas Lüscher

9

object named as

Thomas F Lüscher

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

J Wouter Jukema

12

object named as

J Wouter Jukema

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Ko Willems van Dijk

10

object named as

Ko Willems van Dijk

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

author name string

Susan Kühnast

1

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Sam J L van der Tuin

2

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

José W A van der Hoorn

3

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Jan B van Klinken

4

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Branko Simic

5

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Elsbet Pieterman

6

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Patrick C N Rensen

11

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Hans M G Princen

13

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

publication date

20 August 2014

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

European Heart Journal

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

36

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

39-48

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Niacin Reduces Atherosclerosis Development in APOE*3Leiden.CETP Mice Mainly by Reducing NonHDL-Cholesterol.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4286319

8 July 2018

Mechanisms of acute coronary syndromes and their implications for therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4286319

8 July 2018

Journey through cholesteryl ester transfer protein inhibition: from bench to bedside

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4286319

8 July 2018

Effects of dalcetrapib in patients with a recent acute coronary syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4286319

8 July 2018

Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4286319

8 July 2018

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4286319

8 July 2018

Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4286319

8 July 2018

Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4286319

8 July 2018

On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4286319

8 July 2018

Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4286319

8 July 2018

Anacetrapib, a Novel CETP Inhibitor: Pursuing a New Approach to Cardiovascular Risk Reduction

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4286319

8 July 2018

Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4286319

8 July 2018

Safety of anacetrapib in patients with or at high risk for coronary heart disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4286319

8 July 2018

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4286319

8 July 2018

Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4286319

8 July 2018

Major lipids, apolipoproteins, and risk of vascular disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4286319

8 July 2018

Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4286319

8 July 2018

Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4286319

8 July 2018

Effects of torcetrapib in patients at high risk for coronary events

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4286319

8 July 2018

Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4286319

8 July 2018

Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE*3-Leiden mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4286319

8 July 2018

HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4286319

8 July 2018

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4286319

8 July 2018

Natural genetic variation as a tool in understanding the role of CETP in lipid levels and disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4286319

8 July 2018

Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4286319

8 July 2018

A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4286319

8 July 2018

Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4286319

8 July 2018

Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4286319

28 July 2018

Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHU319

21 January 2018

Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression.

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHU319

21 January 2018

Torcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more proinflammatory lesions than atorvastatin

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHU319

21 January 2018

Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice.

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHU319

21 January 2018

Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHU319

21 January 2018

Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHU319

21 January 2018

Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25142968

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression

1 reference

https://pubmed.ncbi.nlm.nih.gov/25142968

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of cholesteryl ester transfer protein by anacetrapib does not impair the anti-inflammatory properties of high density lipoprotein

1 reference

https://pubmed.ncbi.nlm.nih.gov/25142968

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits

1 reference

https://pubmed.ncbi.nlm.nih.gov/25142968

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE*3-Leiden.CETP mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/25142968

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Aliskiren inhibits atherosclerosis development and improves plaque stability in APOE*3Leiden.CETP transgenic mice with or without treatment with atorvastatin

1 reference

https://pubmed.ncbi.nlm.nih.gov/25142968

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Large and cholesteryl ester-rich high-density lipoproteins in cholesteryl ester transfer protein (CETP) deficiency can not protect macrophages from cholesterol accumulation induced by acetylated low-density lipoproteins

1 reference

https://pubmed.ncbi.nlm.nih.gov/25142968

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1093/EURHEARTJ/EHU319

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34858025&oldid=2142199408"